Seattle institute lands $18m funding to develop RNA vaccine for chikungunya
Pharmaceutical Technology
AUGUST 3, 2023
AAHI is developing a novel RNA vaccine that overcomes manufacturing and storage limitations to increase accessibility.
BioNTech’s RNA vaccine sparks potential in pancreatic cancer
Pharmaceutical Technology
MAY 11, 2023
Results published in Nature for a personalised pancreatic cancer vaccine that uses neoantigens from patients’ tumours have lent further support to early positive signals. The vaccine, developed by BioNTech, led to half of the patients with pancreatic cancer in the Phase I trial remaining cancer-free 18 months later.
RNA 
345
345 Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Sanofi signs mRNA vaccine development deal with IDT Australia
Pharmaceutical Technology
APRIL 16, 2024
Sanofi has signed an agreement with IDT Australia for preclinical formulation development of its messenger RNA (mRNA) vaccines.
Vaccination 147
147 
Pfizer begins plan to challenge Shingrix with an mRNA vaccine
Bio Pharma Dive
FEBRUARY 10, 2023
The pharma and partner BioNTech have kicked off the first human trial of a messenger RNA shot for shingles, believing there’s room to clear the high bar set by GSK’s rival vaccine.
Vaccination 358
358 
BioNTech targets infectious diseases for vaccine development
Pharmaceutical Technology
MARCH 28, 2023
Following on from its Covid-19 vaccine programmes, BioNTech has set its sights on a range of infectious diseases for vaccine development. The company saw major successes with its Covid-19 vaccine, developed in collaboration with Pfizer. In response to the lower vaccine sales forecasts, BioNTech shares opened at 3.9%
Vaccination 276
276 
Merck and Orna partner for RNA technology-based vaccines and therapies
Pharmaceutical Technology
AUGUST 17, 2022
Merck (MSD outside North America) has entered a partnership agreement with Orna Therapeutics for discovering, developing and marketing various programmes based on next-generation RNA technology. These programmes will include therapies and vaccines in infectious disease and oncology areas.
RNA 147
147 
Moderna sues Pfizer, BioNTech over COVID-19 vaccine technology
Bio Pharma Dive
AUGUST 26, 2022
The biotech claims its rivals’ vaccine Comirnaty, one of the world’s top-selling pharmaceutical products, infringes on two patents covering its messenger RNA technology.
Vaccination 256
256 
BioNTech inaugurates mRNA vaccine manufacturing facility in Rwanda
Pharmaceutical Technology
DECEMBER 19, 2023
BioNTech has inaugurated a new messenger RNA (mRNA) vaccine manufacturing facility in Kigali, Rwanda, which will have BioNTainers.
Manufacturing 130
130 
GreenLight and US NIH partner to develop Covid-19 vaccine for variants
Pharmaceutical Technology
AUGUST 1, 2022
GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.
Vaccination 245
245 
HIV vaccines suffer setbacks but new approaches could turn the tide
Pharmaceutical Technology
FEBRUARY 3, 2023
Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.
Vaccination 293
293 
Moderna signs contract to supply Covid-19 booster vaccines to the US
Pharmaceutical Technology
AUGUST 1, 2022
Moderna has entered a new supply contract with the US Government to deliver 66 million doses of its Covid-19 vaccine booster candidate, mRNA-1273.222. The contract comprises a $1.74bn award to produce and supply these vaccine doses and options to further procure up to 234 million additional doses of the company’s booster candidates.
Vaccination 289
289 
Beyond Covid-19: the disruptive potential of RNA-based therapeutics
Pharmaceutical Technology
MARCH 1, 2023
The Covid-19 pandemic led to massive developments and scientific advances within the field of messenger ribonucleic acid (mRNA) vaccines. Pfizer /BioNTech and Moderna’s mRNA-based vaccines were the first to receive emergency use authorisation (EUA) out of all other Covid-19 vaccines under development in late 2020.
RNA 147
147 
Merck and Moderna partner to develop and sell cancer vaccine
Pharmaceutical Technology
OCTOBER 14, 2022
German pharmaceutical firm Merck has extended its partnership with Moderna to jointly develop and sell mRNA-4157/V940, an investigational personalised cancer vaccine (PCV). In 2016, the companies entered a strategic partnership to develop novel messenger RNA (mRNA) based PCVs.
Vaccination 289
289 
New UK intracellular drug delivery centre to support RNA development
Pharmaceutical Technology
JUNE 1, 2023
A new intracellular drug delivery centre will be established in the UK to support potential ribonucleic acid (RNA) vaccines and therapeutics , as well as the development of innovative drug delivery technologies. It will focus on studying and developing new lipid nanoparticle (LNP) formulations for the delivery of RNA medicine.
Drug Delivery 242
242 
ReNAgade Therapeutics enters RNA therapy arena with $300m
Pharmaceutical Technology
MAY 23, 2023
ReNAgade Therapeutics has burst onto the RNA technology scene by announcing a $300m financing round. With its delivery system, Cambridge, Massachusetts-based biotech says it aims to “address major limitations in RNA therapeutics by enabling the delivery of RNA medicines to previously inaccessible tissues and cells in the body.”
RNA 147
147 
Samsung Biologics, GreenLight conclude Covid-19 vaccine engineering run
Pharmaceutical Technology
AUGUST 2, 2022
Samsung Biologics and GreenLight Biosciences have completed the initial commercial-scale engineering run for their messenger ribonucleic acid (mRNA) Covid-19 vaccine under their manufacturing collaboration. Following the demonstration at Samsung, the clinical trial of GreenLight’s Covid-19 booster vaccine is anticipated to commence this year.
Engineer 262
262 
Health Canada grants approval for Moderna’s Covid-19 vaccine in children
Pharmaceutical Technology
JULY 15, 2022
Health Canada has granted approval for the usage of Moderna’s messenger RNA (mRNA) Covid-19 vaccine, Spikevax, in a 25µg two-dose regimen for active immunisation to prevent Covid-19 in children aged six months to five years. So far, children aged below five years were not eligible to receive the Covid-19 vaccine in Canada.
Vaccination 264
264 
Moderna and Pfizer, having shown speed with coronavirus vaccines, see opportunity in seasonal flu
Bio Pharma Dive
SEPTEMBER 17, 2020
Both companies believe the messenger RNA technology they're using in their coronavirus vaccines could be applied to create a better flu shot.
Vaccination 319
319 
Scaling up RNA-LNPs: Strategies for successful and consistent clinical manufacturing
Pharmaceutical Technology
NOVEMBER 2, 2023
While things may have slowed down a little since the rapid approvals of the COVID-19 vaccines, the excitement around RNA-LNP is still going strong.
RNA 130
130 
BioNTech Founders Predict Cancer Vaccine Is Only Years Away
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 16, 2022
The husband-and-wife team who co-founded BioNTech, the biotechnology company that partnered with Pfizer to develop an effective messenger-RNA (mRNA) shot against COVID-19, has predicted that a cancer vaccine could be widely available within the next decade.
Vaccination 175
175 
CSL, Arcturus get first approval for self-assembling RNA jab
pharmaphorum
NOVEMBER 29, 2023
Japan’s medicines regulator has approved the first vaccine based on self-assembling RNA, a spin on the mRNA technology used in current shots, which is designed to deliver greater efficacy with a lower dose.
RNA 115
115 
FDA authorizes Novavax’s COVID-19 vaccine for teens
Bio Pharma Dive
AUGUST 22, 2022
The decision will make a third vaccine available for children 12 to 17 years old in the U.S., giving them an option that doesn’t use the messenger RNA technology of shots by Pfizer and Moderna.
Vaccination 130
130 
The future of RNA-based Therapeutics and Vaccines: Introducing advanced, Unrivalled Treatment Approaches
Roots Analysis
NOVEMBER 6, 2023
RNA-based therapeutics have completely revolutionized the healthcare segment, greatly influencing the study and treatment of human diseases by conferring precise targeting ability to therapeutic modalities. The below figure presents the distribution of next generation RNA-based therapeutics and RNA-based vaccines, based on type of molecule.
RNA 40
40 
HDT Bio receives Emergency Use Approval for Covid-19 vaccine in India
Pharmaceutical Technology
JUNE 30, 2022
HDT Bio has received Emergency Use Approval from Indian regulators for its Covid-19 vaccine, Gemcovac. The vaccine leverages self-amplifying RNA (saRNA), which can replicate itself after administration and could be effective at very low doses. HDT Bio CEO Steve Reed said: “Our saRNA vaccine is a game-changer.
Vaccination 162
162 
Leading innovators in flavivirus vaccine components
Pharmaceutical Technology
FEBRUARY 15, 2023
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Flavivirus vaccine components. Sanofi is one of the leading patent filers for Flavivirus vaccine components.
Vaccination 130
130 
mRNA revolutionized the race for a Covid-19 vaccine. Could cancer be next?
STAT News
NOVEMBER 21, 2022
This story has been adapted from the STAT Report “The future of messenger RNA: Covid-19 vaccines are just the beginning.” Read the rest…
Vaccination 105
105 
Gritstone bio supports mRNA Covid-19 vaccine plans with Phase I publication
Pharmaceutical Technology
JUNE 8, 2023
Gritstone bio has reported interim results from an ongoing Phase 1 study evaluating the company’s self-amplifying mRNA (samRNA) vaccine as a boost against Covid-19 (CORAL-BOOST). The Phase I CORAL-BOOST dose-escalation trial (NCT05148962) evaluated Gritstone’s samRNA candidate (GRT-R910) in previously vaccinated healthy older adults.
Vaccination 130
130 
China’s NMPA grants EUA to CSPC Pharmaceutical’s Covid-19 vaccine
Pharmaceutical Technology
MARCH 23, 2023
China’s National Medical Products Administration (NMPA) has granted emergency use authorisation (EUA) for CSPC Pharmaceutical Group’s messenger RNA (mRNA) vaccine, SYS6006, to treat Covid-19. The independently developed SYS6006 vaccine has been designed to target some major Omicron variants. efficacy after 14 to 28 days.
Vaccination 130
130 
Experimental flu vaccine, developed using mRNA, seen as potential game changer
STAT News
NOVEMBER 24, 2022
An experimental influenza vaccine developed using messenger RNA technology appears capable of inducing what should be a protective immune response against all known subtypes of flu, at least in animals. If the work is translated into humans it could turn out to be a version of a long-sought universal vaccine.
Vaccination 138
138 
Positive initial results for srRNA rabies vaccine
Drug Discovery World
FEBRUARY 19, 2024
Replicate Bioscience has shared positive results from the Phase I trial of RBI-4000, its srRNA-based rabies vaccine. In this clinical trial, evaluating safety and immunogenicity of RBI-4000 , participants received one or two doses of srRNA vaccine at low doses (0.1mcg, 1mcg or 10mcg).
Vaccination 52
52 
H2 2022 to see the decline of Covid-19 vaccines as forecasts decrease
Pharmaceutical Technology
JANUARY 30, 2023
According to GlobalData’s Drugs database, there were 22 prophylactic vaccines in development for COVID-19 with sales forecasts available in H2 2022. Of these 22 vaccines, mRNA-derived vaccines dominate, with Comirnaty and Moderna’s Spikvax accounting for 88% of 2022 sales, with 58% and 30%, respectively.
Vaccination 130
130 
Orbital raises $270m investment for advancement of RNA medicines
Pharmaceutical Technology
APRIL 27, 2023
Orbital Therapeutics has raised $270m in a Series A round led by ARCH Venture Partners to advance a portfolio of programmable RNA therapeutics. Orbital will use the new funding to increase the application of RNA-based medicines for use in the fields of new vaccines, immunomodulation and protein replacement.
RNA 130
130 
COVID-19 Messenger RNA Vaccination and Myocarditis
JAMA Internal Medicine
OCTOBER 3, 2021
Several recent case series have described acute myocarditis after COVID-19 messenger RNA (mRNA) vaccination. While the cardiac complications of vaccines are important, discussion has been limited by small sample sizes that lack gender and racial and ethnic diversity. 414 fully vaccinated individuals). women and 31.2%
RNA 73
73 
UTMB and HDT Bio receive US funding for vaccine development
Pharmaceutical Technology
NOVEMBER 30, 2022
in a project agreement from the US government for developing self-amplifying RNA (saRNA) vaccine technology against advanced and emergent viral threats. Development of vaccines to Phase I trials under the five-year $59m prototype project comprises additional $28.4m in milestone payments.
Vaccination 147
147 
Merck pays startup Orna $150M as ‘circular RNA’ attracts industry interest
Bio Pharma Dive
AUGUST 16, 2022
The pharmaceutical company has formed an alliance with Orna and invested $100 million in its Series B round, hoping the young biotech’s approach could lead to multiple new vaccines and drugs.
RNA 280
280 
Vaccines & virology: Spotlight on advances in vaccine breakthroughs
Drug Discovery World
OCTOBER 2, 2023
This eBook sponsored by DNA Script explores the advances and breakthroughs taking place within vaccines and virology.
Vaccination 52
52 
Moderna reports ‘encouraging’ early data for one of its rare disease medicines
Bio Pharma Dive
MAY 19, 2023
The biotech, best known for its vaccine research, said its clinical trial is the first to report results of a messenger RNA therapeutic designed for intracellular protein replacement.
RNA 287
287 
Moderna seeks FDA EUA for Covid-19 booster vaccine
Pharmaceutical Technology
AUGUST 24, 2022
Mode rna has submitted an application to the US Food and Drug Administration (FDA) to obtain emergency use authorization (EUA) for mRNA-1273.222, its BA.4/BA.5 5 Omicron-targeting bivalent booster vaccine for Covid-19. The submission is made for a 50µg booster dose of the vaccine for usage in adults aged 18 years and above.
Vaccination 130
130 
Merck makes circular RNA play with $3.5bn Orna alliance
pharmaphorum
AUGUST 16, 2022
Merck & Co has ramped up its involvement in the RNA category, partnering with US biotech Orna Therapeutics in a deal valued at up to $3.5 billion, consummating a relationship that first started in 2018 and spanned a range of mRNA-based vaccines for infectious diseases. billion, including $150 million upfront.
RNA 98
98 
Novavax’s Covid-19 vaccine wins backing of CDC advisory panel
STAT News
JULY 19, 2022
An expert panel that advises the Centers for Disease Control and Prevention on vaccine policy voted Tuesday to recommend use of Novavax’s Covid-19 vaccine — an achievement a long time in the making for the Gaithersburg, Md.-based based company.
Vaccination 98
98 
Noxopharm in-licenses novel RNA tech for drug discovery and vaccines
BioPharma Reporter
DECEMBER 6, 2021
Australiaâs Noxopharm has in-licensed novel RNA tech developed by Hudson Institute of Medical Research: focusing on RNA drug discovery and mRNA vaccine manufacture via Noxopharmâs subsidiary Pharmorage.
RNA 52
52 
An mRNA vaccine strategy under study to fight the flu—as a shot and intranasal spray
Medical Xpress
DECEMBER 30, 2022
Messenger RNA vaccine technology, once an arcane area of research, became household terminology because of the COVID-19 pandemic, and now scientists are working on an mRNA flu vaccine strategy that, at least in this study, involves a first dose administered as a shot but a booster administered as an mRNA nasal spray.
Vaccination 111
111 
Alnylam Files Lawsuits Against Pfizer and Moderna Over Patent Infringement of RNA Delivery Technology
XTalks
MARCH 21, 2022
Credited as a pioneering RNA interference (RNAi) therapeutics company, Alnylam Pharmaceuticals is taking Pfizer and Moderna to court, claiming that the companies’ use of the lipid nanoparticle (LNP)-based RNA delivery technology in their mRNA COVID-19 vaccines infringes on a patented technology.
RNA 98
98 
Listen: How blockbusters get made, new vaccines for RSV, and mRNA’s Q score
STAT News
JANUARY 19, 2023
And do normal people care about messenger RNA? We also discuss the latest news in the life sciences, including new vaccines for a vexing infection and the future of mRNA. Where do new drugs come from? Does science need billionaires? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast.
Vaccination 115
115 
Let's personalize your content